secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001682852-26-000012
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna receives FDA Refusal-to-File for flu vaccine mRNA-1010; no impact on 2026 guidance
--------------------------------------------------------------------------------

- FDA CBER refused to review BLA for mRNA-1010 citing comparator choice, not safety/efficacy.
- Moderna states RTF letter contradicts prior written feedback from pre-Phase 3 and pre-submission meetings.
- Moderna has requested a Type A meeting with FDA to discuss path forward.
- mRNA-1010 accepted for review in EU, Canada, Australia; earliest approval late 2026/early 2027.
- Company reaffirms no change to 2026 financial guidance despite RTF.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285226000012/0001682852-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285226000012/mrna-20260203.htm
  HTML page:      https://secwatch.observer/filing/0001682852-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer